Reijnders F J, Thomas C M, Doesburg W H, Rolland R, Eskes T K
Catholic University, Institute ofObstetrics and Gynaecology, Nijmegen, The Netherlands.
Br J Obstet Gynaecol. 1988 May;95(5):462-8. doi: 10.1111/j.1471-0528.1988.tb12797.x.
The clinical and endocrine effects of progestogen therapy in early pregnancy were investigated using a double-blind randomized trial in 64 patients who had a viable fetus at 6 weeks gestation and had an increased risk of miscarriage. The patients were randomly allocated to receive either 17 alpha-hydroxyprogesterone caproate or a placebo between 7 and 12 weeks gestation. Four fetal ultrasonographic variables and 17 maternal endocrine variables were studied in each woman. Only four maternal serum variables (17 alpha-hydroxyprogesterone, prolactin, thyroxin and thyroxin binding globulin) rose significantly. The serum progesterone levels in the hormone supplemented group were on average 20% higher than in the placebo group but the difference was not statistically significant. However, the relation between the progesterone levels and the fetal outcome was not clear. Therefore it is not advisable to prescribe 17-OHP-C during early pregnancy to prevent a miscarriage.
采用双盲随机试验，对64例妊娠6周时胎儿存活且有流产风险增加的患者，研究了孕早期孕激素治疗的临床和内分泌效应。患者在妊娠7至12周之间被随机分配接受己酸17α-羟孕酮或安慰剂。对每位女性研究了四个胎儿超声变量和17个母体内分泌变量。只有四个母体血清变量（17α-羟孕酮、催乳素、甲状腺素和甲状腺素结合球蛋白）显著升高。激素补充组的血清孕酮水平平均比安慰剂组高20%，但差异无统计学意义。然而，孕酮水平与胎儿结局之间的关系尚不清楚。因此，在孕早期开具17-OHP-C以预防流产是不可取的。
